Rev Esp Quimioter 2023;36(Suppl.1):25-28

Clinical experience in the treatment of COVID-19 with monoclonal antibodies in solid organ transplant recipients

ELENA MÚÑEZ-RUBIO, JORGE CALDERÓN-PARRA, ANDREA GUTIÉRREZ-VILLANUEVA, ANA FERNÁNDEZ-CRUZ, ANTONIO RAMOS-MARTÍNEZ

Published: 24 November 2023

http://www.doi.org/10.37201/req/s01.07.2023

ABSTRACT
Solid organ transplant (SOT) recipients are at high risk for complications from coronavirus disease 2019 (COVID-19). SOT recipients mount lower immunological responses to vaccines than general population and are at high risk for breakthrough COVID-19 infections. Passive immunotherapy in the form of anti-Spike monoclonal antibodies (MoAbs) may be an alternative for the prophylaxis and treatment of COVID-19 in these patients. SARS-CoV-2 has evolved by accumulating resistance mutations that have escaped the neutralizing action of most MoAbs. However, MoAbs directed at more conserved epitopes and that maintain effector functions could maintain efficacy in the treatment of these patients. According to published data, SOT recipients with low anti-spike antibody responses to vaccination could benefit from the use of MoAbs in pre-exposure prophylaxis, in the treatment of COVID-19 mild to moderate and severe COVID-19 with less than 15 days of symptom duration and low oxygen requirements. Combination therapy could be more effective than monotherapy for the treatment of mild-to-moderate SARS-CoV-2 infection.

Rev Esp Quimioter 2023; 36(Suppl.1):25-28 [Full-text PDF]